Known targets — ChEMBL curated mechanism
PPARDPTGS1PTGS2dacAdacBdacCftsImrcAmrcBmrdA
The experimentally established mechanism targets of Lysine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GSR | P00390 | 2/20 | 0.71 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.54 |
| ▸ | ARG2 | P78540 | 4/20 | 0.46 |
| ▸ | ARG1 | P05089 | 3/20 | 0.46 |
| ▸ | RNPEP | Q9H4A4 | 1/20 | 0.44 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.44 |
| ▸ | GRM8 | O00222 | 1/20 | 0.44 |
| ▸ | GRM6 | O15303 | 1/20 | 0.44 |
| ▸ | GRIN2D | O15399 | 1/20 | 0.44 |
| ▸ | GRIN3B | O60391 | 1/20 | 0.44 |
| ▸ | GRIK1 | P39086 | 1/20 | 0.44 |
| ▸ | GRM5 | P41594 | 1/20 | 0.44 |
| ▸ | GRIA1 | P42261 | 1/20 | 0.44 |
| ▸ | GRIA2 | P42262 | 1/20 | 0.44 |
| ▸ | GRIA3 | P42263 | 1/20 | 0.44 |
| ▸ | SLC1A3 | P43003 | 1/20 | 0.44 |
| ▸ | SLC1A2 | P43004 | 1/20 | 0.44 |
| ▸ | SLC1A1 | P43005 | 1/20 | 0.44 |
| ▸ | GRIA4 | P48058 | 1/20 | 0.44 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Lysine SCHEMBL4435147 | 1.00 | GSR (0.71) | GSRSMN1; SMN2ARG2ARG1RNPEP | |
| Lysine SCHEMBL27946776 | 0.98 | GSR (0.69) | GSRSMN1; SMN2ARG2ARG1RNPEP | |
| Lysine SCHEMBL11175666 | 0.98 | GSR (0.69) | GSRSMN1; SMN2ARG2ARG1RNPEP | |
| Ornithine SCHEMBL3793499 | 0.95 | GSR (0.62) | GSRSMN1; SMN2ARG2ARG1CYP1A2 | |
| Ornithine SCHEMBL11171112 | 0.93 | GSR (0.60) | GSRSMN1; SMN2ARG2ARG1CYP1A2 | |
| Lysine SCHEMBL2589784 | 0.87 | GSR (0.80) | GSRARG2ARG1RNPEPCYP1A2 | |
| Lysine SCHEMBL31679370 | 0.87 | GSR (0.80) | GSRARG2ARG1RNPEPCYP1A2 | |
| Lysine SCHEMBL1425215 | 0.87 | GSR (0.80) | GSRARG2ARG1RNPEPCYP1A2 | |
| Lysine SCHEMBL20952564 | 0.87 | GSR (0.80) | GSRARG2ARG1RNPEPCYP1A2 | |
| Lysine SCHEMBL18528930 | 0.87 | GSR (0.80) | GSRARG2ARG1RNPEPCYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 87 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4682242-A1 | SOLUTION FOR SUSPENDING CELLS, AND USE OF SAME | GAIA BioMedicine Inc. (JP) | 2026-01-21 | — | — | EP | disclosed |
| CN-118973911-A | Content filling system | 大日本印刷株式会社 | 2024-11-15 | — | — | CN | disclosed |
| US-20240366673-A1 | METHOD FOR TREATING CELLS | GAIA BIOMEDICINE INC. (JP) | 2024-11-07 | — | — | US | disclosed |
| WO-2024190864-A1 | SOLUTION FOR SUSPENDING CELLS, AND USE OF SAME | 株式会社ガイアバイオメディシン | 2024-09-19 | — | — | WO | disclosed |
| EP-4400576-A1 | METHOD FOR TREATING CELLS | GAIA BioMedicine Inc. (JP) | 2024-07-17 | — | — | EP | disclosed |
| CN-118103492-A | Method for treating cells | 盖亚生物制药有限公司 | 2024-05-28 | — | — | CN | disclosed |
| US-11890372-B2 | Transfusion preparation | OTSUKA PHARMACEUTICAL FACTORY, INC. (JP) | 2024-02-06 | — | — | US | disclosed |
| WO-2023190412-A1 | CONTENT FILLING SYSTEM | 大日本印刷株式会社 | 2023-10-05 | — | — | WO | disclosed |
| WO-2023190411-A1 | CONTENT FILLING SYSTEM | 大日本印刷株式会社 | 2023-10-05 | — | — | WO | disclosed |
| US-20230263858-A1 | NUTRITION FORMULATION | OTSUKA PHARMACEUTICAL FACTORY, INC. (JP) | 2023-08-24 | — | — | US | disclosed |
| EP-0712583-A2 | Total parenteral nutrition solution containing watersoluble vitamin B | TANABE SEIYAKU CO., LTD. (JP) | 1996-05-22 | — | — | EP | disclosed |
| EP-0704199-A1 | TRANSFUSION CONTAINER, TRANSFUSION PREPARATION, AND COMPREHENSIVE VITAMIN-CONTAINING HIGH-CALORIE TRANSFUSION PREPARATION | THE GREEN CROSS CORPORATION (JP) | 1996-04-03 | — | — | EP | disclosed |
| EP-0700681-A1 | NUTRITIONAL TRANSFUSION FOR PERIPHERAL VEIN ADMINISTRATION | THE GREEN CROSS CORPORATION (JP) | 1996-03-13 | — | — | EP | disclosed |
| EP-0671166-A2 | Nutrient-supplying preparation | THE GREEN CROSS CORPORATION (JP) | 1995-09-13 | — | — | EP | disclosed |
| EP-0560989-A1 | ENTERAL PREPARATION FOR CANCER THERAPY | OTSUKA PHARMACEUTICAL FACTORY, INC. (JP) | 1993-09-22 | — | — | EP | disclosed |
| EP-0312612-B1 | NUTRITIVE EMULSION | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 1993-03-24 | — | — | EP | disclosed |
| EP-0510687-A2 | Infusion preparation | THE GREEN CROSS CORPORATION (JP) | 1992-10-28 | — | — | EP | disclosed |
| EP-0312612-A1 | NUTRITIVE EMULSION | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 1989-04-26 | — | — | EP | disclosed |
| CN-1031025-A | NUTRITIVE EMULSION PREPARATION | OTSUKA PHARMA CO LTD (JP) | 1989-02-15 | — | — | CN | disclosed |
| US-4420432-A | Crystalline salt of basic L-amino acid with L-malic acid and process for the preparation thereof | TANABE SEIYAKU CO., LTD. (JP) | 1983-12-13 | — | — | US | disclosed |